title: Polycystic kidney disease.
abstract: Polycystic kidney disease, an inherited systemic disorder, is characterized by the development of multiple cysts in the kidneys and other organs. Patients can present at any age, but more often come to clinical attention (unless there is a family history) after age 30. Patients who are diagnosed before age 30 have a worse renal survival. Although palpation of the abdomen occasionally provides a clue to the presence of polycystic kidney disease, radiographic procedures most often suggest the diagnosis. Mutations in the PKD1 or PKD2 genes give rise to cyst formation. Flank pain, hematuria, polyuria, nephrolithiasis, urinary tract infections, and hypertension may be part of the syndrome of polycystic kidney disease. It is the fourth most common cause of end-stage renal disease. Blood pressure treatment goals are less than 130/80 mm Hg. Treatment should include the use of angiotensin-converting enzyme inhibitors.
authors.affiliation: Section of Hypertension and Clinical Pharmacology, Medical College of Georgia, Augusta, GA 30912, USA.
authors.forename: Pamela J
authors.initials: PJ
authors.lastname: Fall
authors.forename: L Michael
authors.initials: LM
authors.lastname: Prisant
mesh_terms: D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D000959:Antihypertensive Agents / Q000627:therapeutic use; D001794:Blood Pressure / Q000187:drug effects; D006801:Humans; D006973:Hypertension / Q000175:diagnosis / Q000188:drug therapy / Q000503:physiopathology; D008279:Magnetic Resonance Imaging; D007690:Polycystic Kidney Diseases / Q000175:diagnosis / Q000188:drug therapy / Q000503:physiopathology; D018084:Ultrasonography, Interventional
chemical_list: D000806:Angiotensin-Converting Enzyme Inhibitors; D000959:Antihypertensive Agents